NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
08 mai 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
-- Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (“HeFH”) ahead of schedule; topline results expected in 2H...
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
24 avr. 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options ---- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and...
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
03 avr. 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
31 mars 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected...
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
01 mars 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, March 01, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
09 févr. 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
17 janv. 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) ---- Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm ----...
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
19 déc. 2022 16h01 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the...
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients
23 nov. 2022 08h00 HE
|
NewAmsterdam Pharma Company B.V.
-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on...